Site Search

Search
Showing 1 - 10 of 14 results
Medications
Study of Ivacaftor in Children Ages 1 to 2 Shows Positive Results

Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.

News |
| 2 min read
About the CF Foundation | Medications
Walgreens and Cystic Fibrosis Foundation Form Alliance to Operate Cystic Fibrosis Specialty Pharmacy

Aim is to Provide Cystic Fibrosis Patients Enhanced Access to Medications and Expanded Pharmacy Services

Press Release |
| 4 min read
Medications
Positive Results from Two Phase 3 Clinical Studies of Tezacaftor (VX-661) and Ivacaftor

Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.

News |
| 4 min read
About the CF Foundation | Medications
Walgreens Completes Transaction to Gain Ownership Stake in Cystic Fibrosis Specialty Pharmacy

Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.

Press Release |
| 3 min read
About the CF Foundation | Medications | Drug Pipeline
Foundation Executive Vice President for Medical Affairs Quoted in NY Times
News |
| 1 min read
Research | Drug Pipeline | Medications
FDA Accepts Vertex Application for Expansion of Trikafta to Include Children ages 6-11

Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021. 

News |
| 2 min read